Display options
Cite
Chiquette E, Oral EA, Garg A, et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;10:375-383doi: 10.2147/DMSO.S130810.
Chiquette, E., Oral, E. A., Garg, A., Araújo-Vilar, D., & Dhankhar, P. (2017). Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes, metabolic syndrome and obesity : targets and therapy, 10375-383. https://doi.org/10.2147/DMSO.S130810
Chiquette, Elaine, et al. "Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 10 (2017): 375-383. doi: https://doi.org/10.2147/DMSO.S130810
Chiquette E, Oral EA, Garg A, Araújo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017 Sep 13;10:375-383. doi: 10.2147/DMSO.S130810. eCollection 2017. PMID: 29066925; PMCID: PMC5604558.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab Syndr Obes. 2017 Sep 13;10:375-383. doi: 10.2147/DMSO.S130810. eCollection 2017.

Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges.

Diabetes, metabolic syndrome and obesity : targets and therapy

Elaine Chiquette, Elif A Oral, Abhimanyu Garg, David Araújo-Vilar, Praveen Dhankhar

Affiliations

  1. Aegerion Pharmaceuticals, Cambridge, MA, USA.
  2. Brehm Center for Diabetes Research and Metabolism, Endocrinology and Diabetes Division, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  3. Division of Nutrition and Metabolic Diseases, Department of Internal Medicine, Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  4. Department of Medicine, UETeM, CIMUS School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.
  5. Complete HEOR Solutions (CHEORS), North Wales, PA, USA.

PMID: 29066925 PMCID: PMC5604558 DOI: 10.2147/DMSO.S130810

Abstract

BACKGROUND: Lipodystrophy (LD; non-human immunodeficiency virus [HIV]-associated) syndromes are a rare body of disorders for which true prevalence is unknown. Prevalence estimates of rare diseases are important to increase awareness and financial resources. Current qualitative and quantitative estimates of LD prevalence range from ~0.1 to 90 cases/million. We demonstrate an approach to quantitatively estimate LD prevalence (all, generalized, and partial) through a search of 5 electronic medical record (EMR) databases and 4 literature searches.

METHODS: EMR and literature searches were conducted from 2012 to 2014. For the EMR database searches (Quintiles, IMS LifeLink, General Electric Healthcare, and Humedica EMR), LD cases were identified by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 272.6 (United Kingdom General Practice Research Database used other diagnostic codes to identify LD) plus additional LD-associated clinical characteristics (patients with HIV or documented HIV treatment were excluded). Expert adjudication of cases was used for the Quintiles database only. Literature searches (PubMed and EMBASE) were conducted for each of the 4 major LD subtypes. Prevalence estimates were determined by extrapolating the total number of cases identified for each search to the database population (EMR search) and European population (literature search).

RESULTS: The prevalence range of all LD across all EMR databases was 1.3-4.7 cases/million. For the adjudicated Quintiles search, the estimated prevalence of diagnosed LD was 3.07 cases/million (95% confidence interval [CI], 2.30-4.02), 0.23 cases/million (95% CI, 0.06-0.59) and 2.84 cases/million (95% CI, 2.10-3.75) for generalized lipodystrophy (GL) and partial lipodystrophy (PL), respectively. For all literature searches, the prevalence of all LD in Europe was 2.63 cases/million (0.96 and 1.67 cases/million for GL and PL, respectively).

CONCLUSION: LD prevalence estimates are at the lower range of previously established numbers, confirming that LD is an ultra-rare disease. The establishment of diagnostic criteria and coding specific to the 4 major LD subtypes and future studies/patient registries are needed to further refine our estimates.

Keywords: adipose tissue; atypical diabetes; dyslipidemia; hypertriglyceridemia; insulin resistance; lipodystrophy; prevalence

Conflict of interest statement

Disclosure EC is an employee and stockholder of Aegerion Pharmaceuticals. EAO has worked as a consultant/advisor to and has received grant/drug support from Amylin, Bristol-Myers Squibb, AstraZeneca,

References

  1. Medicine (Baltimore). 2004 Jan;83(1):18-34 - PubMed
  2. J Clin Endocrinol Metab. 2009 Jan;94(1):10-6 - PubMed
  3. Diabetes Care. 2013 Aug;36(8):2142-5 - PubMed
  4. Medicine (Baltimore). 2003 Mar;82(2):129-46 - PubMed
  5. Orphanet J Rare Dis. 2014 Nov 18;9:173 - PubMed
  6. Pediatr Surg Int. 2012 Dec;28(12):1211-7 - PubMed
  7. Nat Genet. 2017 Jan;49(1):17-26 - PubMed
  8. Eur Heart J. 2014 Aug 21;35(32):2146-57 - PubMed
  9. J Clin Endocrinol Metab. 2011 Nov;96(11):3313-25 - PubMed
  10. J Clin Endocrinol Metab. 2016 Jul;101(7):2759-67 - PubMed
  11. QJM. 2011 Nov;104(11):971-9 - PubMed
  12. J Clin Endocrinol Metab. 1999 Jan;84(1):170-4 - PubMed
  13. Am J Med. 2000 Feb;108(2):143-52 - PubMed
  14. N Engl J Med. 2004 Mar 18;350(12):1220-34 - PubMed
  15. Arch Dermatol Res. 2015 May;307(4):291-8 - PubMed
  16. Endocr Pract. 2013 Jan-Feb;19(1):107-16 - PubMed
  17. J Clin Endocrinol Metab. 2016 Dec;101(12 ):4500-4511 - PubMed

Publication Types

Grant support